For instance, the HMLER breast cancer cell line, which naturally overexpresses CD44, was treated with low-dose paclitaxel (10 nM for four days), leading to a subpopulation enriched in CD44+ cells (>30%), termed HMLER fiscal cells [54]. This evidence concerns the gene CD44 and breast carcinoma.